We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BLK:NYSEBlackRock, Inc. Analysis

Data as of 2026-03-09 - not real-time

$957.67

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

BlackRock’s stock is currently trading below its short‑term moving averages and the RSI signals oversold conditions, while the MACD histogram remains negative, indicating bearish momentum. The beta above one and elevated 30‑day volatility point to heightened price swings, yet the DCF fair‑value estimate suggests a substantial upside potential. The trailing P/E sits well above the asset‑management industry average, but the forward P/E compresses, and a dividend yield near 2% adds income appeal.
Recent material news highlights a dividend increase and a first‑quarter dividend payout, but also underscores stress in the private‑credit space with large redemption requests and a loan write‑off that pressured the share price. Analyst consensus remains bullish with a “buy” rating and an upgraded price target, reflecting confidence in revenue growth, strong cash generation, and the firm’s market position. Balancing the technical weakness with solid fundamentals and upside from valuation models leads to a nuanced view: short‑term caution, medium‑term buying opportunity, and long‑term confidence.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Technical indicators show oversold momentum and bearish MACD
  • Recent redemption pressure and loan write‑off increase near‑term uncertainty
  • Elevated volatility and beta suggest heightened price swings

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • DCF valuation indicates significant upside
  • Strong revenue growth and cash flow generation
  • Attractive dividend yield with sustainable payout ratio

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Market‑leading scale and diversified global footprint
  • Consistent earnings growth and robust balance sheet
  • Long‑term dividend sustainability and defensive cash position

Key Metrics & Analysis

Financial Health

Revenue Growth23.40%
Profit Margin22.93%
P/E Ratio27.1
ROE10.72%
ROA3.47%
Debt/Equity24.37
P/B Ratio2.7
Op. Cash Flow$3.9B
Free Cash Flow$7.0B
Industry P/E17.4

Technical Analysis

TrendNeutral
RSI26.5
Support$919.03
Resistance$1,113.56
MA 20$1,061.76
MA 50$1,085.82
MA 200$1,085.51
MACDBearish
VolumeIncreasing
Fear & Greed Index100

Valuation

Fair Value$1,614.39
Target Price$1,320.94
Upside/Downside37.93%
GradeUndervalued
TypeBlend
Dividend Yield2.40%

Risk Assessment

Beta1.14
Volatility32.58%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.